Better Buy: AbbVie vs. Johnson & Johnson

AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are stalwart companies that are in a lot of investors' portfolios. AbbVie is strictly pharmaceutical, but its recent purchase of Allergan really broadens its pipeline beyond the world's top-selling drug, Humira, which treats many auto-immune disorders. Pharmaceutical sales make up slightly more than half of Johnson & Johnson's revenue with its consumer health and medical devices bringing in the rest of its sales.